Case Study · Primary Biliary Cholangitis (Rare Disease)
A rare disease rescue.
21 hepatology sites, faster than expected.
How AcceleTrial helped a global biopharma company rapidly add specialist PBC sites to an ongoing study, clearing legal CDA cycles and compressed timelines through platform automation.
The Challenge
Rare disease. Rescue context.
Legal and clinical timelines running in parallel.
Adding sites to an ongoing rare disease study while navigating compressed timelines and legal CDA cycles required a platform capable of managing multiple parallel workflows without losing speed.
The sponsor needed 20 additional clinical sites for a Primary Biliary Cholangitis study. PBC is a rare disease with a limited pool of sites that have genuine hepatology expertise and the right patient population.
Legal CDA negotiation had to run in parallel with clinical feasibility outreach and document collection, all within a compressed rescue timeline.
As a rescue engagement, urgency was elevated. Sites needed to be activated efficiently and quickly. Any delay in identification or document execution had immediate impact on the study's enrollment trajectory.
The Solution
21 hepatology sites.
2 to 3 days, plus internal CDA support.
Using AcceleTrial, LINEA System identified 21 sites with specific hepatology trial expertise and the right PBC patient access profile. Turnaround for feasibility and CDAs was 2 to 3 days, exceeding the sponsor's expectations.
LINEA incorporated its internal CDA negotiation service to handle the legal cycle in parallel with clinical qualification. All study documents were collected at a 50% faster rate. Sites were evaluated across trial history, COVID-readiness, debarment status, and clinical experience.
Outcomes
Rescue delivered.
Rare disease expertise at speed.
21 hepatology specialist sites identified against a target of 20, each qualified against protocol criteria for this rare PBC indication.
18 of LINEA's 21 sites received pre-study visit (PSV) approval, an 86% PSV approval rate from a rescue-context site pool.
Feasibility and CDAs completed in 2 to 3 days, including LINEA's internal CDA negotiation, exceeding sponsor expectations.
All necessary study documents collected at a 50% faster rate, eliminating manual coordination delays.
Get the Full Story
Download the case study
or see AcceleTrial live
Get the one-page PDF summary or request a personalized demo using your protocol and therapeutic area.